ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dexamethasone

Also written as “dexamethasone”, “OTO-104” and “Dexycu”.

Its studies are mostly in Multiple Myeloma · Cataract · Macular Edema · Meniere Disease · Conjunctivitis, Allergic, led by 30 companies.

Drug pageDexamethasone: every studyMany companies study it; this page follows only the 92 they lead. All 1,797 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 6, 200392 company-led studies, 7 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb200 open or runningphase 3since Mar 6, 2003Mar 6, 2003none ahead
Ocular Therapeutixits history only100 open or runningphase 3since Jan 9, 2014Jan 9, 2014none ahead
Takedaits history only100 open or runningphase 4since May 30, 2017Jul 25, 2007none ahead
Oculisits history only50 open or runningphase 3since Sep 2, 2021Oct 16, 2019none ahead
Sun Pharmaceutical Industriesits history only50 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Oncotherapeuticsits history only40 open or runningphase 2since Aug 26, 2008Aug 26, 2008none ahead
EyePoint Pharmaceuticalsits history only30 open or runningphase 4since Dec 13, 2021Dec 13, 2021none ahead
Hamad Medicalits history only32 open or runningphase 3since Nov 30, 2020Jan 12, 2010none ahead
Sanofiits history only33 open or runningphase 2since Oct 20, 2020Oct 20, 2020Apr 1, 2027phase 2 · NCT06356571
Alconits history only20 open or runningphase 4since Feb 29, 2008Feb 29, 2008none ahead

Also a collaborator on its studies: Karyopharm Therapeutics, AbbVie, Onyx Therapeutics, Abbott, Tigermed Consulting, Accelovance, ORA, Johnson & Johnson, Hoffmann-La Roche, Amgen, Novum Pharmaceutical Research Services, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Mar 6, 2003.

  1. May 14, 2007Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT00474188 · 26 enrolled · United States, Australia, Canada
  2. May 23, 2007Phase 3 study in RecurrenceNCT00478777 · 150 enrolled · Germany
  3. Nov 6, 20072 phase 1 studies in Multiple MyelomaNCT00555100, NCT00560352
  4. Jun 2, 2008Phase 3 study in Multiple MyelomaNCT00689936 · 1,623 enrolled · United States, Australia, Austria and more
  5. Jun 9, 2009Phase 3 study in Multiple MyelomaNCT00928486 · 25 enrolled · Japan
  6. Nov 8, 2010Phase 3 study in LymphomaNCT01239797 · 646 enrolled · United States, Australia, Austria and more
  7. Apr 10, 2012Phase 1 study in Multiple MyelomaNCT01575925 · 25 enrolled · United States, Canada
  8. May 4, 2012Phase 2 study in Multiple MyelomaNCT01593410 · 194 enrolled · China
  9. Oct 1, 2012Phase 2 study in Multiple MyelomaNCT01698801 · 26 enrolled · Japan
  10. Jun 28, 2013Phase 3 study in Newly Diagnosed, Previously Untreated Multiple MyelomaNCT01891643 · 23 enrolled · United States, Greece, Italy and more
  11. Sep 17, 2013Phase 2 study in Multiple MyelomaNCT01946477 · 186 enrolled · United States, Canada, Japan and more
  12. Dec 10, 20132 phase 2 studies in Multiple MyelomaNCT02011113, NCT02045017
  13. Jan 23, 2015Phase 2 study in Multiple MyelomaNCT02348528 · 65 enrolled · China
  14. Aug 16, 2018Phase 3 study in Multiple MyelomaNCT03651128 · 386 enrolled · United States, Belgium, Canada and more
  15. Aug 6, 2023Named dexamethasoneINNProposed as its International Nonproprietary Name in WHO's List 129 · before, OTO-104

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
TriamcinoloneruleResearch Insightphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

All 20 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03651128Multiple Myeloma · United States, Belgium, Canada and more3CompletedApr 13, 2026386
NCT02348528Multiple Myeloma · China2CompletedSep 29, 201665
NCT02045017Multiple Myeloma · Austria, France, Germany and more2CompletedJan 27, 201781
NCT02011113Multiple Myeloma · Japan2CompletedSep 201436
NCT01946477Multiple Myeloma · United States, Canada, Japan and more2CompletedApr 30, 2025186
NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more3TerminatedJun 25, 202023
NCT01698801Multiple Myeloma · Japan2CompletedNov 26, 201326
NCT01593410Multiple Myeloma · China2CompletedJan 3, 2013194
NCT01575925Multiple Myeloma · United States, Canada1CompletedAug 7, 201825
NCT01239797Lymphoma · United States, Australia, Austria and more3CompletedSep 2, 2014646
NCT00928486Multiple Myeloma · Japan3CompletedSep 10, 201025
NCT00689936Multiple Myeloma · United States, Australia, Austria and more3CompletedJul 14, 20161,623
NCT00560352Multiple Myeloma · United States, France, Italy and more1TerminatedFeb 201116
NCT00555100Multiple Myeloma · Japan1CompletedDec 1, 201015
NCT00478777Recurrence · Germany3CompletedNov 2007150
NCT00474188Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada2TerminatedDec 200826
NCT00424047Multiple Myeloma · Australia, Austria, Belgium and more3CompletedNov 1, 2005351
NCT00420849Multiple Myeloma · Australia, Austria, Ireland and more3CompletedOct 2009587
NCT00179647Multiple Myeloma · United States, Canada3CompletedDec 20081,913
NCT00056160Multiple Myeloma · United States, Canada3CompletedNov 1, 2005353

How it is read

Names in the registry

  • “Dexamethasone”, 94 entries
  • “dexamethasone”, 20 entries
  • “OTO-104”, 9 entries
  • “Dexycu”, 4 entries
  • “Dexamethasone Oral”, 3 entries

Codes read as this program: OCS01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.